[Histonet] Ab validation

Thu Oct 23 12:51:19 CDT 2008

Yes, we would reevaluate and get the new procedures signed-off by our director.

Linda A. Sebree
University of Wisconsin Hospital & Clinics
IHC/ISH Laboratory
DB1-223 VAH
600 Highland Ave.
Madison, WI 53792
(608)265-6596

-----Original Message-----
From: histonet-bounces <@t> lists.utsouthwestern.edu [mailto:histonet-bounces <@t> lists.utsouthwestern.edu] On Behalf Of pkromund <@t> gundluth.org
Sent: Thursday, October 23, 2008 12:39 PM
To: Patti Loykasek
Cc: histonet-bounces <@t> lists.utsouthwestern.edu; histonet
Subject: Re: [Histonet] Ab validation

Would you agree that if you change the pretreatment vessel you would have
to revalidate all your antibodies? Or if you change your pretreatment
solution to an all in one solution that deparaffinizes & does HIER that you
would also have to revalidate all your antibodies.
Pam

             Patti Loykasek                                                
             <ploykasek <@t> phenop                                             
             ath.com>                                                   To 
             Sent by:                  histonet                            
             histonet-bounces@         <histonet <@t> pathology.swmed.edu>      
             lists.utsouthwest                                          cc 
             ern.edu                                                       
                                                                   Subject 
                                       [Histonet] Ab validation            
             02/01/2008 01:53                                              
             PM                                                            

------ Forwarded Message
From: Patti Loykasek <ploykasek <@t> phenopath.com>
Date: Fri, 01 Feb 2008 11:18:26 -0800
To: <Warren_Eddings <@t> ssmhc.com>
Subject: Re: [Histonet] Re: Histonet Digest, Vol 51, Issue 2

I'll try to formulate a brief answer to the question of validating
antibodies. If you are doing IHC both CLIA and CAP have regulations that
involve validation of antibodies. These regulations cover  Establishment
and
Verification of Method Performance Specifications.  The validation process
is designed to confirm the ability of the antibody to recognize the target
antigen in normal and diseased tissues where it is reasonably expected to
localize. And that there is  not  any obvious unexpected expression; in
other words, to determine its specificity and sensitivity.
To validate antibodies for IHC it's a multiple step process. First you
would
need to determine the working titer, pretreatment, detection & chromogen
that you are going to use. Use your standard SOPS. Use a control that
contains the antigen in question plus some negative elements. You don't
want
a control that is a high expressor or too low of an expresser at this
point.
Once you¹ve determined your working parameters, you need to test the
antibody on normal tissue & diseased tissue that does & does not contain
the
antigen. For example, if you are validating an antibody that is positive in
Lung carcinomas you would want to use lung carcinomas (should be positive),
& a variety of carcinomas, lymphomas, etc... That should be negative. You
may find that this antibody is positive in GI carcinoma, too & you would
want to document that & know what % of GI carcinomas are positive, Also,
run
some normal tissues & assess their positive & negative rate. W compare our
findings with the published literature. You need to document all this work
(
if you don¹t document it, it didn¹t happen). Excel or some other software
is
good for documenting your findings. We have a template that we use for all
work ups (& a validation SOP).
Hope this helps. Good luck.

Patti Loykasek BS, HTL, QIHC
PhenoPath Laboratories
Seattle, WA

>
>  does anyone validate antibody and how do you = do it?
>    _________________________________________________________________
>
>
>
>
>
>
>
> Con=  fidentiality  Notice:  This  email  message, including any
>  attachments,  is  for  = the sole use of the intended recipient(s) and
>  may   contain   confidential   and  =  privileged  information.  Any
>  unauthorized   review,   use,   disclosure   or   distr=   ibution  is
>  prohibited.  If you are not the intended recipient, please cont= act
>  the  sender  by  reply  email  and  destroy all copies of the original
>  messag= e.
>
>
> _______________________________________________
> Histonet mailing list
> Histonet <@t> lists.utsouthwestern.edu
> http://lists.utsouthwestern.edu/mailman/listinfo/histonet
>

------ End of Forwarded Message

This e-mail message, including any attachments, is for the sole use of the
intended recipients and may contain privileged information. Any
unauthorized
review, use, disclosure or distribution is prohibited. If you are not the
intended
recipient, please contact the sender by e-mail and destroy all copies of
the
original message, or you may call PhenoPath Laboratories, Seattle, WA
U.S.A.
at (206) 374-9000.
_______________________________________________
Histonet mailing list
Histonet <@t> lists.utsouthwestern.edu
http://lists.utsouthwestern.edu/mailman/listinfo/histonet

_______________________________________________
Histonet mailing list
Histonet <@t> lists.utsouthwestern.edu
http://lists.utsouthwestern.edu/mailman/listinfo/histonet